Importantly, patients enrolling in this trial will be treated with first-line immunotherapy as is now the standard of care, and the trial will provide further insight on the role of LAT for oligometastatic NSCLC in the immunotherapy era. The gene discussed is LAT; the disease is non-small cell lung carcinoma.